NT Pharma cuts 2025 loss estimate after HK$15.40 million one-off gain from debt-for-equity swap

Bulletin Express

Mar 30

China NT Pharma Group Company Limited (NT Pharma) has revised its profit warning for the year ended 31 December 2025, projecting a narrower net loss of RMB10.90 million–RMB15.90 million after recognising a one-off, non-cash gain of HK$15.40 million (approximately RMB14.10 million).

The gain arises from the issuance of new shares to settle outstanding debt, which reduces the previously anticipated loss by the same HK$15.40 million amount. All other details in the company’s 26 February 2026 profit warning remain unchanged.

NT Pharma’s board will meet on 31 March 2026 to approve and publish the audited annual results for 2025. Shareholders and potential investors are advised to review the forthcoming results announcement and exercise caution in trading the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1199070282"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199070282\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199070282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199070282","market":"us","top_or_hot":-1,"title":"NT Pharma cuts 2025 loss estimate after HK$15.40 million one-off gain from debt-for-equity swap","media":"Bulletin Express","content":"<p>China NT Pharma Group Company Limited (NT Pharma) has revised its profit warning for the year ended 31 December 2025, projecting a narrower net loss of RMB10.90 million–RMB15.90 million after recognising a one-off, non-cash gain of HK$15.40 million (approximately RMB14.10 million).</p>\n<p>The gain arises from the issuance of new shares to settle outstanding debt, which reduces the previously anticipated loss by the same HK$15.40 million amount. All other details in the company’s 26 February 2026 profit warning remain unchanged.</p>\n<p>NT Pharma’s board will meet on 31 March 2026 to approve and publish the audited annual results for 2025. Shareholders and potential investors are advised to review the forthcoming results announcement and exercise caution in trading the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT Pharma cuts 2025 loss estimate after HK$15.40 million one-off gain from debt-for-equity swap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT Pharma cuts 2025 loss estimate after HK$15.40 million one-off gain from debt-for-equity swap\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-30 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China NT Pharma Group Company Limited (NT Pharma) has revised its profit warning for the year ended 31 December 2025, projecting a narrower net loss of RMB10.90 million–RMB15.90 million after recognising a one-off, non-cash gain of HK$15.40 million (approximately RMB14.10 million).</p>\n<p>The gain arises from the issuance of new shares to settle outstanding debt, which reduces the previously anticipated loss by the same HK$15.40 million amount. All other details in the company’s 26 February 2026 profit warning remain unchanged.</p>\n<p>NT Pharma’s board will meet on 31 March 2026 to approve and publish the audited annual results for 2025. Shareholders and potential investors are advised to review the forthcoming results announcement and exercise caution in trading the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1199070282","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199070282","pubTimestamp":1774880767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China NT Pharma Group Company Limited (NT Pharma) has revised its profit warning for the year ended 31 December 2025, projecting a narrower net loss of RMB10.90 million–RMB15.90 million after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药"},"translate_title":"债转股一次性收益1540万港元泰凌医药下调2025年亏损预估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"China NT Pharma Group Company Limited (NT Pharma) has revised its profit warning for the year ended 31 December 2025, projecting a narrower net loss of RMB10.90 million–RMB15.90 million after recognising a one-off, non-cash gain of HK$15.40 million (approximately RMB14.10 million).\nThe gain arises from the issuance of new shares to settle outstanding debt, which reduces the previously anticipated loss by the same HK$15.40 million amount. All other details in the company’s 26 February 2026 profit warning remain unchanged.\nNT Pharma’s board will meet on 31 March 2026 to approve and publish the audited annual results for 2025. Shareholders and potential investors are advised to review the forthcoming results announcement and exercise caution in trading the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}